Phocas Financial Corp. Cuts Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Phocas Financial Corp. trimmed its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 85.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,407 shares of the specialty pharmaceutical company’s stock after selling 93,053 shares during the quarter. Phocas Financial Corp.’s holdings in Supernus Pharmaceuticals were worth $593,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Barclays PLC grew its stake in Supernus Pharmaceuticals by 88.3% in the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock valued at $3,393,000 after purchasing an additional 51,005 shares during the period. Segall Bryant & Hamill LLC bought a new position in Supernus Pharmaceuticals in the 3rd quarter worth about $791,000. Geode Capital Management LLC boosted its position in shares of Supernus Pharmaceuticals by 5.3% in the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock valued at $46,218,000 after acquiring an additional 74,438 shares during the period. Franklin Resources Inc. grew its stake in Supernus Pharmaceuticals by 7.6% during the third quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock valued at $987,000 after acquiring an additional 2,121 shares in the last quarter. Finally, Empowered Funds LLC bought a new stake in Supernus Pharmaceuticals during the 4th quarter worth approximately $1,498,000.

Supernus Pharmaceuticals Stock Up 0.4 %

NASDAQ:SUPN opened at $32.81 on Wednesday. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.53 and a twelve month high of $40.28. The stock has a market cap of $1.81 billion, a P/E ratio of 30.66 and a beta of 0.90. The business’s 50-day moving average price is $37.34 and its two-hundred day moving average price is $35.39.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 700 shares of Supernus Pharmaceuticals stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total transaction of $27,734.00. Following the completion of the sale, the vice president now owns 10,149 shares of the company’s stock, valued at $402,103.38. The trade was a 6.45 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now owns 7,853 shares of the company’s stock, valued at $307,444.95. The trade was a 10.56 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,104 shares of company stock worth $440,263 over the last three months. 9.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald downgraded shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut their price target for the company from $57.00 to $36.00 in a report on Wednesday, February 19th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.